0001493152-21-007824.txt : 20210401
0001493152-21-007824.hdr.sgml : 20210401
20210401214647
ACCESSION NUMBER: 0001493152-21-007824
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210330
FILED AS OF DATE: 20210401
DATE AS OF CHANGE: 20210401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boehm Marcus
CENTRAL INDEX KEY: 0001850698
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35817
FILM NUMBER: 21800424
MAIL ADDRESS:
STREET 1: C/O VYANT BIO, INC.
STREET 2: 201 ROUTE 17 NORTH, 2ND FLOOR
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vyant Bio, Inc.
CENTRAL INDEX KEY: 0001349929
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 043462475
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
BUSINESS PHONE: 201.528.9200
MAIL ADDRESS:
STREET 1: 2370 STATE ROUTE 70 WEST
STREET 2: SUITE 310
CITY: CHERRY HILL,
STATE: NJ
ZIP: 08002
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS, INC
DATE OF NAME CHANGE: 20111216
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS INC
DATE OF NAME CHANGE: 20060117
4
1
ownership.xml
X0306
4
2021-03-30
0
0001349929
Vyant Bio, Inc.
VYNT
0001850698
Boehm Marcus
C/O VYANT BIO, INC. 2 EXECUTIVE CAMPUS
2370 STATE ROUTE 70, SUITE 310
CHERRY HILL,
NJ
08002
1
0
0
0
Common Stock, $0.0001 par value
2021-03-30
4
J
0
93929
A
93929
D
Stock option (right to buy)
1.56
2021-03-30
4
J
0
5068
0
A
2021-03-30
2030-12-01
Common Stock
5068
5068
D
Stock option (right to buy)
1.56
2021-03-30
4
J
0
1619
0
A
2021-03-30
2030-06-05
Common Stock
1619
1619
D
Stock option (right to buy)
0.96
2021-03-30
4
J
0
15547
0
A
2021-03-30
2027-06-20
Common Stock
15547
15547
D
Stock option (right to buy)
4.61
2021-03-30
4
A
0
13015
0
A
2021-03-30
2031-03-30
Common Stock
13015
13015
D
Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
Pursuant to the Merger Agreement, Reporting Person received options to purchase up to shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. These options are currently exercisable.
/s/ John A. Roberts, attorney-in-fact
2021-04-01